<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Sci</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Sci</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1349-7006</journal-id><journal-id journal-id-type="publisher-id">CAS</journal-id><journal-title-group><journal-title>Cancer Science</journal-title></journal-title-group><issn pub-type="ppub">1347-9032</issn><issn pub-type="epub">1349-7006</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27566263</article-id><article-id pub-id-type="pmc">5132270</article-id><article-id pub-id-type="doi">10.1111/cas.13066</article-id><article-id pub-id-type="publisher-id">CAS13066</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Pharmacologic study (<styled-content style="fixed-case">JP</styled-content>28927) of alectinib in Japanese patients with ALK+ non&#x02010;small&#x02010;cell lung cancer with or without prior crizotinib therapy</article-title><alt-title alt-title-type="left-running-head">Hida <italic>et&#x000a0;al</italic>.</alt-title></title-group><contrib-group><contrib id="cas13066-cr-0001" contrib-type="author" corresp="yes"><name><surname>Hida</surname><given-names>Toyoaki</given-names></name><address><email>107974@aichi-cc.jp</email></address><xref ref-type="aff" rid="cas13066-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cas13066-cr-0002" contrib-type="author"><name><surname>Nakagawa</surname><given-names>Kazuhiko</given-names></name><xref ref-type="aff" rid="cas13066-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="cas13066-cr-0003" contrib-type="author"><name><surname>Seto</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="cas13066-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="cas13066-cr-0004" contrib-type="author"><name><surname>Satouchi</surname><given-names>Miyako</given-names></name><xref ref-type="aff" rid="cas13066-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="cas13066-cr-0005" contrib-type="author"><name><surname>Nishio</surname><given-names>Makoto</given-names></name><xref ref-type="aff" rid="cas13066-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="cas13066-cr-0006" contrib-type="author"><name><surname>Hotta</surname><given-names>Katsuyuki</given-names></name><xref ref-type="aff" rid="cas13066-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="cas13066-cr-0007" contrib-type="author"><name><surname>Takahashi</surname><given-names>Toshiaki</given-names></name><xref ref-type="aff" rid="cas13066-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="cas13066-cr-0008" contrib-type="author"><name><surname>Ohe</surname><given-names>Yuichiro</given-names></name><xref ref-type="aff" rid="cas13066-aff-0008">
<sup>8</sup>
</xref><xref ref-type="aff" rid="cas13066-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="cas13066-cr-0009" contrib-type="author"><name><surname>Takeda</surname><given-names>Koji</given-names></name><xref ref-type="aff" rid="cas13066-aff-0010">
<sup>10</sup>
</xref></contrib><contrib id="cas13066-cr-0010" contrib-type="author"><name><surname>Tatsuno</surname><given-names>Masahiro</given-names></name><xref ref-type="aff" rid="cas13066-aff-0011">
<sup>11</sup>
</xref></contrib><contrib id="cas13066-cr-0011" contrib-type="author"><name><surname>Asakawa</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="cas13066-aff-0012">
<sup>12</sup>
</xref></contrib><contrib id="cas13066-cr-0012" contrib-type="author"><name><surname>Shimada</surname><given-names>Tadashi</given-names></name><xref ref-type="aff" rid="cas13066-aff-0012">
<sup>12</sup>
</xref></contrib><contrib id="cas13066-cr-0013" contrib-type="author"><name><surname>Tanaka</surname><given-names>Tomohiro</given-names></name><xref ref-type="aff" rid="cas13066-aff-0012">
<sup>12</sup>
</xref></contrib><contrib id="cas13066-cr-0014" contrib-type="author"><name><surname>Tamura</surname><given-names>Tomohide</given-names></name><xref ref-type="aff" rid="cas13066-aff-0008">
<sup>8</sup>
</xref><xref ref-type="aff" rid="cas13066-aff-0013">
<sup>13</sup>
</xref></contrib></contrib-group><aff id="cas13066-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Department of Thoracic Oncology</named-content><institution>Aichi Cancer Center</institution><named-content content-type="city">Nagoya</named-content><country country="JP">Japan</country></aff><aff id="cas13066-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Department of Medical Oncology</named-content><institution>Kindai University Faculty of Medicine</institution><named-content content-type="city">Osaka</named-content><country country="JP">Japan</country></aff><aff id="cas13066-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Department of Thoracic Oncology</named-content><institution>National Kyusyu Cancer Center</institution><named-content content-type="city">Fukuoka</named-content><country country="JP">Japan</country></aff><aff id="cas13066-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">Department of Thoracic Oncology</named-content><institution>Hyogo Cancer Center</institution><named-content content-type="city">Akashi</named-content><country country="JP">Japan</country></aff><aff id="cas13066-aff-0005"><label><sup>5</sup></label><named-content content-type="organisation-division">Department of Thoracic Medical Oncology</named-content><institution>The Cancer Institute Hospital of Japanese Foundation for Cancer Research</institution><named-content content-type="city">Tokyo</named-content><country country="JP">Japan</country></aff><aff id="cas13066-aff-0006"><label><sup>6</sup></label><named-content content-type="organisation-division">Department of Allergy and Respiratory Medicine</named-content><institution>Okayama University Hospital</institution><named-content content-type="city">Okayama</named-content><country country="JP">Japan</country></aff><aff id="cas13066-aff-0007"><label><sup>7</sup></label><named-content content-type="organisation-division">Department of Thoracic Oncology</named-content><institution>Shizuoka Cancer Center</institution><named-content content-type="city">Shizuoka</named-content><country country="JP">Japan</country></aff><aff id="cas13066-aff-0008"><label><sup>8</sup></label><named-content content-type="organisation-division">Department of Thoracic Oncology</named-content><institution>National Cancer Center Hospital</institution><named-content content-type="city">Tokyo</named-content><country country="JP">Japan</country></aff><aff id="cas13066-aff-0009"><label><sup>9</sup></label><institution>National Cancer Center East</institution><named-content content-type="city">Chiba</named-content><country country="JP">Japan</country></aff><aff id="cas13066-aff-0010"><label><sup>10</sup></label><named-content content-type="organisation-division">Department of Medical Oncology</named-content><institution>Osaka City General Hospital</institution><named-content content-type="city">Osaka</named-content><country country="JP">Japan</country></aff><aff id="cas13066-aff-0011"><label><sup>11</sup></label><named-content content-type="organisation-division">Translational Clinical Research Science &#x00026; Strategy Department</named-content><institution>Chugai Pharmaceutical Co. Ltd.</institution><named-content content-type="city">Tokyo</named-content><country country="JP">Japan</country></aff><aff id="cas13066-aff-0012"><label><sup>12</sup></label><named-content content-type="organisation-division">Clinical Science &#x00026; Strategy Department</named-content><institution>Chugai Pharmaceutical Co. Ltd.</institution><named-content content-type="city">Tokyo</named-content><country country="JP">Japan</country></aff><aff id="cas13066-aff-0013"><label><sup>13</sup></label><named-content content-type="organisation-division">Thoracic Center</named-content><institution>St. Luke's International Hospital</institution><named-content content-type="city">Tokyo</named-content><country country="JP">Japan</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Toyoaki Hida, Aichi Cancer Center, 1&#x02010;1 Kanokoden, Chikusa&#x02010;ku, Nagoya 464&#x02010;8681, Japan.<break/>
Tel: +81&#x000a0;52&#x000a0;762&#x000a0;6111; Fax: +81 52 759 3676;<break/>
E&#x02010;mail: <email>107974@aichi-cc.jp</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="ppub"><month>11</month><year>2016</year></pub-date><volume>107</volume><issue>11</issue><issue-id pub-id-type="doi">10.1111/cas.2016.107.issue-11</issue-id><fpage>1642</fpage><lpage>1646</lpage><history><date date-type="received"><day>26</day><month>5</month><year>2016</year></date><date date-type="rev-recd"><day>22</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>25</day><month>8</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 Japanese Cancer Association <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. Cancer Science published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japanese Cancer Association.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:CAS-107-1642.pdf"/><abstract id="cas13066-abs-0001"><p>We report pharmacokinetics, efficacy and safety data for a new 150&#x02010;mg alectinib capsule in <italic><styled-content style="fixed-case">ALK</styled-content>+</italic> non&#x02010;small&#x02010;cell lung cancer in a multicenter, open&#x02010;label pharmacologic study (<styled-content style="fixed-case">JP</styled-content>28927). Eligible patients (&#x02265;20&#x000a0;years, locally advanced/metastatic <italic><styled-content style="fixed-case">ALK</styled-content>+</italic> disease, <styled-content style="fixed-case">ALK</styled-content> inhibitor&#x02010;na&#x000ef;ve and &#x02010;pretreated [including crizotinib refractory]) were randomized 1:1 to receive one of two sequences of alectinib 300&#x000a0;mg twice daily (comprising different schedules of 20/40&#x02010;mg and 150&#x02010;mg capsules) until investigator&#x02010;determined lack of clinical benefit. Co&#x02010;primary endpoints were: bioequivalence of alectinib 20/40&#x000a0;mg <italic>vs</italic> 150&#x000a0;mg; food effect with 150&#x000a0;mg; and safety. Thirty&#x02010;five patients were enrolled; median treatment duration was 13.1&#x000a0;months (range 1.1&#x02212;15.0). Under fasting conditions, exposure of the two formulations was similar; mean <styled-content style="fixed-case">AUC</styled-content>
<sub>last</sub>&#x000a0;&#x000b1;&#x000a0;standard deviation 3230&#x000a0;&#x000b1;&#x000a0;914&#x000a0;h&#x000b7;ng/<styled-content style="fixed-case">mL </styled-content>
<italic>vs</italic> 3710&#x000a0;&#x000b1;&#x000a0;1040&#x000a0;h&#x000b7;ng/<styled-content style="fixed-case">mL</styled-content>, respectively, for 150&#x02010;mg <italic>vs</italic> 20/40&#x02010;mg capsules. Food effect with 150&#x000a0;mg alectinib was negligible. Treatment&#x02010;related adverse events in &#x0003e;20% of patients were constipation (31.4%), dysgeusia (25.7%), and decreased white blood cell and neutrophil count (22.9% each). No treatment&#x02010;related grade 4/5 events occurred. Median time to response was 1.2&#x000a0;months (95% <styled-content style="fixed-case">CI</styled-content> 1.1&#x02212;2.1). For the full analysis set (<italic>n&#x000a0;=&#x000a0;</italic>35) and crizotinib&#x02010;failure subpopulations (<italic>n&#x000a0;=&#x000a0;</italic>23), the overall response rate was 70.0% (95% <styled-content style="fixed-case">CI</styled-content> 50.6&#x02212;85.3) and 65.0% (95% <styled-content style="fixed-case">CI</styled-content> 40.8&#x02212;84.6), and median progression&#x02010;free survival was 13.9&#x000a0;months (95% <styled-content style="fixed-case">CI</styled-content> 11.1&#x02212;not reached) and 12.9&#x000a0;months (95% <styled-content style="fixed-case">CI</styled-content> 3.9&#x02212;not reached), respectively. The 150&#x02010;mg capsule had a similar exposure profile to 20/40&#x02010;mg capsules. Alectinib demonstrated promising efficacy and was well tolerated.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cas13066-kwd-0001">Alectinib</kwd><kwd id="cas13066-kwd-0002">anaplastic lymphoma kinase</kwd><kwd id="cas13066-kwd-0003">bioequivalence</kwd><kwd id="cas13066-kwd-0004">Japanese</kwd><kwd id="cas13066-kwd-0005">non&#x02010;small&#x02010;cell lung cancer</kwd></kwd-group><funding-group><award-group><funding-source>Chugai Pharmaceutical Co. Ltd.</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Pfizer</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Novartis</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Pfizer Japan Inc</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Novartis Pharma</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Astellas Pharma</funding-source></award-group></funding-group><funding-group><award-group><funding-source>AstraZeneca</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Ono Pharmaceutical</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Bristol&#x02010;Myers Squibb</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Eli Lilly Japan</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Taiho Pharmaceutical</funding-source></award-group></funding-group><funding-group><award-group><funding-source>MSD</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Takeda Pharmaceutical</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Daiichi Sankyo</funding-source></award-group></funding-group><funding-group><award-group><funding-source>Quintiles</funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="4"/><page-count count="5"/><word-count count="4837"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>cas13066</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>November 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.8 mode:remove_FC converted:29.11.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="cas13066-cit-1001">
<source>Cancer Sci</source>
<volume>107</volume> (<year>2016</year>) <fpage>1642</fpage>&#x02013;<lpage>1646</lpage>
<pub-id pub-id-type="pmid">27566263</pub-id></mixed-citation>
</p></notes><notes><fn-group id="cas13066-ntgp-0001"><fn id="cas13066-note-1001"><p>
<bold>Funding Information</bold>
</p><p>This work was supported by Chugai Pharmaceutical Co. Ltd. No grant number is applicable.</p></fn><fn id="cas13066-note-1002"><p>
<bold>Clinical trial number</bold>
</p><p>JapicCTI&#x02010;132186.</p></fn></fn-group></notes></front><body><p>Lung cancer is the leading cause of cancer&#x02010;related mortality worldwide.<xref rid="cas13066-bib-0001" ref-type="ref">1</xref> However, recent advances in knowledge of the molecular genotype of lung tumors have led to a revolution in the diagnosis and treatment of the disease. The anaplastic lymphoma kinase (<italic>ALK</italic>) gene is frequently involved in translocations that lead to gene fusions in a variety of malignancies, including lung cancer. It is estimated that <italic>ALK</italic> gene rearrangements occur in 4&#x02013;5% of all patients with advanced non&#x02010;small&#x02010;cell lung cancer (NSCLC).<xref rid="cas13066-bib-0002" ref-type="ref">2</xref>
</p><p>Transforming rearrangements of the <italic>ALK</italic> gene were initially identified in anaplastic large&#x02010;cell lymphoma.<xref rid="cas13066-bib-0003" ref-type="ref">3</xref> In 2007, a novel fusion oncogene that resulted in the expression of EML4&#x02010;ALK fusion proteins was identified in NSCLC.<xref rid="cas13066-bib-0004" ref-type="ref">4</xref>, <xref rid="cas13066-bib-0005" ref-type="ref">5</xref>, <xref rid="cas13066-bib-0006" ref-type="ref">6</xref>
<italic>ALK+</italic> tumor cells displayed oncogenic behavior, being dependent on signaling from ALK fusion proteins for their survival.<xref rid="cas13066-bib-0005" ref-type="ref">5</xref>, <xref rid="cas13066-bib-0007" ref-type="ref">7</xref> This observation formed the basis of targeting <italic>ALK</italic> as a therapeutic approach for the treatment of <italic>ALK+</italic> NSCLC.</p><p>In 2011, the ALK inhibitor crizotinib was approved by the US Food and Drug Administration for the first&#x02010;line treatment of advanced <italic>ALK+</italic> NSCLC.<xref rid="cas13066-bib-0008" ref-type="ref">8</xref> Approval was partly based on a phase&#x000a0;I study that reported an overall response rate (ORR) of 57% and a 6&#x02010;month progression&#x02010;free survival (PFS) rate of 72%.<xref rid="cas13066-bib-0009" ref-type="ref">9</xref> In 2014, ceritinib was granted accelerated approval in the USA for patients with <italic>ALK+</italic> NSCLC who experienced disease progression (PD) or who were intolerant to crizotinib; approval was based on ORR of 58% (crizotinib na&#x000ef;ve) and 56% (crizotinib pretreated) and a median PFS of 7.0&#x000a0;months.<xref rid="cas13066-bib-0010" ref-type="ref">10</xref>
</p><p>In 2014, alectinib, a central nervous system&#x02010;penetrant and highly selective ALK inhibitor, was granted approval by the Japanese Ministry of Health, Labour and Welfare for the treatment of <italic>ALK+</italic>, unresectable, advanced or recurrent NSCLC in Japan. Approval was based on data from ALK inhibitor&#x02010;na&#x000ef;ve patients with <italic>ALK+</italic> NSCLC who received alectinib 300&#x000a0;mg twice daily in a phase I/II study (AF&#x02010;001JP). Alectinib was well tolerated and highly active, with &#x0003e;90% (43/46) of patients achieving an objective response.<xref rid="cas13066-bib-0011" ref-type="ref">11</xref> Follow&#x02010;up is ongoing and, to date, 19.6% of patients have achieved a complete response (CR) and the 2&#x02010;year PFS rate is 76%.<xref rid="cas13066-bib-0012" ref-type="ref">12</xref>, <xref rid="cas13066-bib-0013" ref-type="ref">13</xref>
</p><p>Patients given alectinib in 20/40&#x02010;mg capsules must take eight capsules to reach the recommended clinical dose of 300&#x000a0;mg.<xref rid="cas13066-bib-0011" ref-type="ref">11</xref> As this can be burdensome and could decrease compliance, we undertook the current study to demonstrate the bioequivalence of a new 150&#x02010;mg capsule of alectinib <italic>vs</italic> the 20/40&#x02010;mg capsules in patients with <italic>ALK+</italic> NSCLC. We also investigated the safety and efficacy of alectinib in <italic>ALK+</italic> NSCLC, including patients who had failed on crizotinib.</p><sec id="cas13066-sec-0002"><title>Patients and Methods</title><p>This multicenter, open&#x02010;label, randomized study (JP28927) examined the bioequivalence and the effect of food on the bioavailability of 150&#x02010;mg and 20/40&#x02010;mg capsules of alectinib under fasting conditions in patients with <italic>ALK+</italic> NSCLC (JapicCTI&#x02010;132186).</p><p>Patients were randomly assigned using a permuted block randomization method in a 1:1 ratio to one of two groups to receive alectinib 300&#x000a0;mg twice daily in cycle 1 (30&#x000a0;days). The study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The protocol was reviewed and approved by the institutional review boards of the participating institutions, and written informed consent was obtained from all patients.</p><sec id="cas13066-sec-0003"><title>Treatment</title><p>Patients in group A received alectinib 20/40&#x02010;mg capsules for 10&#x000a0;days (fasting), followed by 150&#x02010;mg capsules for 10&#x000a0;days (fasting), then 150&#x02010;mg capsules for 10&#x000a0;days (non&#x02010;fasting state) (Fig.&#x000a0;S1). Patients in group&#x000a0;B received alectinib 150&#x02010;mg capsules for 10&#x000a0;days (fasting), followed by 20/40&#x02010;mg capsules for 10&#x000a0;days (fasting), then 150&#x02010;mg capsules for 10&#x000a0;days (non&#x02010;fasting state). A washout period of 2&#x000a0;weeks was required between the last dose of crizotinib/prior ALK inhibitor and the first dose of alectinib. After cycle 1, patients received 150&#x02010;mg alectinib capsules until investigator&#x02010;determined lack of clinical benefit.</p></sec><sec id="cas13066-sec-0004"><title>Patients</title><p>Eligible patients were aged &#x02265;20&#x000a0;years, had histologically or cytologically confirmed advanced or metastatic <italic>ALK</italic>&#x02010;rearranged, stage IIIB/IV, or recurrent NSCLC, and an Eastern Cooperative Oncology Group performance status of 0&#x02013;1. Prior treatment, including other ALK inhibitors, was allowed. Patients with meningeal or symptomatic brain metastases, or those who had received prior alectinib treatment, were excluded.</p></sec><sec id="cas13066-sec-0005"><title>Endpoints</title><p>The primary endpoints were to evaluate: the bioequivalence of 300&#x000a0;mg twice&#x02010;daily alectinib with 20/40&#x02010;mg capsules <italic>vs</italic> 150&#x02010;mg capsules under fasting conditions; the effect of food on the pharmacokinetics of alectinib after repeated oral administration of the 150&#x02010;mg capsule after meals; and safety. Secondary endpoints included investigator&#x02010;assessed ORR, PFS, time to response, duration of response and disease control rate (DCR). Efficacy and safety analyses were also undertaken in a subgroup of patients who had failed prior crizotinib.</p></sec><sec id="cas13066-sec-0006"><title>Assessments</title><p>Blood samples for pharmacokinetic analysis were collected pre&#x02010;dose and at 0.5, 1, 2, 4, 6, 8 and 10&#x000a0;h post&#x02010;dose. Plasma alectinib concentrations were quantified using a liquid chromatography&#x02013;mass spectrometry method with a lower limit of quantification of 0.10&#x000a0;ng/mL.<xref rid="cas13066-bib-0011" ref-type="ref">11</xref>
</p><p>Tumor response and progression were assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 at baseline, days 31 and 59, and then every 56&#x000a0;days. ORR was defined as the percentage of patients with a CR or partial response (PR) according to RECIST. Time to response was calculated from the first administration of alectinib until the date when the criteria for PR/CR were first met, with duration of response calculated from the date of first meeting the criteria for PR/CR until the date of confirmed PD/death, whichever occurred first. DCR comprised CR, PR and stable disease according to RECIST. PFS was calculated from the date of first administration of alectinib until the date of first PD or death, whichever occurred first. Adverse events (AE) were graded according to NCI&#x02010;CTCAE version 4.03. The full analysis set (FAS) included all patients who were treated and eligible; all patients who received at least one dose of alectinib were included in the safety analysis population.</p><p>Anaplastic lymphoma kinase status was confirmed using FISH. A multiplex RT&#x02010;PCR test was also carried out on cells or frozen tissue sections. Patients were deemed to be positive for <italic>ALK</italic> fusion gene expression when FISH and/or RT&#x02010;PCR showed positive results.</p></sec><sec id="cas13066-sec-0007"><title>Statistical analysis</title><p>Sample size was determined using the intra&#x02010;individual variability of trough concentration data from the phase I/II parts of study AF&#x02010;001JP.<xref rid="cas13066-bib-0011" ref-type="ref">11</xref> The population pharmacokinetics model used in AF&#x02010;001JP was also employed; the sample size, which had 80% power to detect bioequivalence in the area under the plasma concentration&#x02013;time curve from time zero to the time of last alectinib concentration (AUC<sub>last</sub>) and the maximum concentration (<italic>C</italic>
<sub>max</sub>), was estimated to be 30 patients.</p><p>Pharmacokinetic parameters for individual plasma concentration data were estimated using a non&#x02010;compartmental method (Phoenix WinNonlin version 6.2; Certara, Cary, NC, USA); estimates and 90% confidence interval (CI) geometric mean ratios were derived from a mixed model (SAS version 9.2; SAS institute, Cary, NC, USA). Kaplan&#x02013;Meier methodology was used to estimate the distribution of time to response, duration of response, and PFS. No formal comparisons were made between the FAS and crizotinib&#x02010;failure populations.</p><p>Time to response, ORR, duration of response, and DCR were analyzed using data from patients who had measurable disease at baseline.</p></sec></sec><sec id="cas13066-sec-0008"><title>Results</title><p>Patients were enrolled between July and September 2013 (Fig.&#x000a0;S2). Data are presented as of 6 November 2014 (the last patient's last visit). Thirty&#x02010;five patients with <italic>ALK+</italic> NSCLC were recruited and randomly assigned to the two groups (Figs S1,S2); all were eligible for the FAS and safety populations. Twenty&#x02010;nine patients (82.9%) had received at least one prior ALK inhibitor. Of 28 patients who had received previous crizotinib treatment, 23 were defined as crizotinib failures.</p><p>Median patient age was 45&#x000a0;years (range 21&#x02013;78) for the FAS population and 43&#x000a0;years (range 21&#x02013;64) for the crizotinib&#x02010;failure population (Table&#x000a0;<xref rid="cas13066-tbl-0001" ref-type="table-wrap">1</xref>). All patients had adenocarcinoma and most patients had received two or more prior chemotherapy regimens.</p><table-wrap id="cas13066-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of the full analysis set and the crizotinib&#x02010;failure population</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Characteristic</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">FAS population (<italic>n</italic>&#x000a0;=&#x000a0;35)<xref ref-type="fn" rid="cas13066-note-0003">&#x02020;</xref>
</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Crizotinib failure<xref ref-type="fn" rid="cas13066-note-0003">&#x02021;</xref> (<italic>n</italic>&#x000a0;=&#x000a0;23)<xref ref-type="fn" rid="cas13066-note-0003">&#x000a7;</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Number of patients</th><th align="left" valign="top" rowspan="1" colspan="1">%</th><th align="left" valign="top" rowspan="1" colspan="1">Number of patients</th><th align="left" valign="top" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" colspan="5" rowspan="1">Age, years</td></tr><tr><td align="left" rowspan="1" colspan="1">Median</td><td align="left" colspan="2" rowspan="1">45.0</td><td align="left" colspan="2" rowspan="1">43.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Range</td><td align="left" colspan="2" rowspan="1">21&#x02212;78</td><td align="left" colspan="2" rowspan="1">21&#x02212;64</td></tr><tr><td align="left" colspan="5" rowspan="1">Gender</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">45.7</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">43.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">54.3</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">56.5</td></tr><tr><td align="left" colspan="5" rowspan="1">ECOG PS</td></tr><tr><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">42.9</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">43.5</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">57.1</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">56.5</td></tr><tr><td align="left" colspan="5" rowspan="1">Smoking status</td></tr><tr><td align="left" rowspan="1" colspan="1">Never</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">60.0</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">65.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Current</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2.9</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">4.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Former</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">37.1</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">30.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Adenocarcinoma</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">100.0</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">100.0</td></tr><tr><td align="left" colspan="5" rowspan="1">Number of prior ALK inhibitors</td></tr><tr><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">17.1</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">65.7</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">82.6</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">17.1</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">17.4</td></tr><tr><td align="left" colspan="5" rowspan="1">Number of prior chemotherapy regimens</td></tr><tr><td align="left" rowspan="1" colspan="1">0&#x02013;1</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">17.1</td><td align="left" rowspan="1" colspan="1">&#x02013;</td><td align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">31.4</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">30.4</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265;3</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">51.4</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">69.6</td></tr></tbody></table><table-wrap-foot><fn id="cas13066-note-0003"><p>&#x02020;28/35 patients were crizotinib pretreated (of which, 5 patients also received ceritinib and 1 patient also received ASP3026); 1 patient received only ceritinib treatment. &#x02021;Failure: patients experienced disease progression on crizotinib. &#x000a7;Including 3 patients who failed on ceritinib. ALK, anaplastic lymphoma kinase; ECOG PS, Eastern Cooperative Oncology Group performance status; FAS, full analysis set.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><sec id="cas13066-sec-0009"><title>Bioequivalence</title><p>Under fasting conditions, exposure of the 150&#x02010;mg alectinib capsule was similar to that of the 20/40&#x02010;mg capsules: mean <italic>C</italic>
<sub>max</sub>&#x000a0;&#x000b1;&#x000a0;SD, 390&#x000a0;&#x000b1;&#x000a0;103&#x000a0;ng/mL <italic>vs</italic> 460&#x000a0;&#x000b1;&#x000a0;122&#x000a0;ng/mL; AUC<sub>last</sub>&#x000a0;&#x000b1;&#x000a0;SD, 3230&#x000a0;&#x000b1;&#x000a0;914&#x000a0;h&#x000b7;ng/mL <italic>vs</italic> 3710&#x000a0;&#x000b1;&#x000a0;1040&#x000a0;h&#x000b7;ng/mL, respectively (Fig.&#x000a0;S3a). The ratios of geometric mean were 0.868 (90% CI 0.801&#x02212;0.941) for AUC<sub>last</sub> and 0.846 (90% CI 0.784&#x02212;0.913) for <italic>C</italic>
<sub>max</sub> for the 150&#x02010;mg capsule <italic>vs</italic> the 20/40&#x02010;mg capsules (Table&#x000a0;<xref rid="cas13066-tbl-0002" ref-type="table-wrap">2</xref>). Although the lower limit of the <italic>C</italic>
<sub>max</sub> 90% CI was slightly below the criteria for bioequivalence (0.80&#x02013;1.25),<xref rid="cas13066-bib-0014" ref-type="ref">14</xref> the AUC<sub>last</sub> met the criteria.</p><table-wrap id="cas13066-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Bioequivalence analysis of 20/40&#x02010;mg alectinib capsules <italic>vs</italic> the 150&#x02010;mg capsule</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="3" valign="top" colspan="1">PK parameter</th><th align="left" rowspan="3" valign="top" colspan="1">Number of patients</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Geometric LSM</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Ratio of geometric LSM</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">20/40&#x02010;mg capsule</th><th align="left" rowspan="2" valign="top" colspan="1">150&#x02010;mg capsule</th><th align="left" rowspan="2" valign="top" colspan="1">Estimate</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">90% CI</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Lower</th><th align="left" valign="top" rowspan="1" colspan="1">Upper</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">AUC, h&#x000b7;ng/mL</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">3570</td><td align="left" rowspan="1" colspan="1">3100</td><td align="left" rowspan="1" colspan="1">0.868</td><td align="left" rowspan="1" colspan="1">0.801</td><td align="left" rowspan="1" colspan="1">0.941</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>C</italic>
<sub>max</sub>, ng/mL</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">445</td><td align="left" rowspan="1" colspan="1">377</td><td align="left" rowspan="1" colspan="1">0.846</td><td align="left" rowspan="1" colspan="1">0.784</td><td align="left" rowspan="1" colspan="1">0.913</td></tr></tbody></table><table-wrap-foot><fn id="cas13066-note-0004"><p>AUC, area under the curve; CI, confidence interval; <italic>C</italic>
<sub>max</sub>, maximum plasma concentration; LSM, least squares mean; PK, pharmacokinetics.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="cas13066-sec-0010"><title>Food effect</title><p>Exposure (<italic>C</italic>
<sub>max</sub> and AUC<sub>last</sub>) from the 150&#x02010;mg capsule in the non&#x02010;fasting state was approximately 20% higher than that in the fasting state, but this difference was within the interindividual variability range, and the effect of food on the pharmacokinetics of alectinib was considered negligible (Fig.&#x000a0;S3b).</p></sec><sec id="cas13066-sec-0011"><title>Safety</title><p>For patients taking the 20/40&#x02010;mg and 150&#x02010;mg capsules, all grade treatment&#x02010;related AE occurring in &#x0003e;20% of patients were constipation (31.4%), dysgeusia (25.7%), and a decrease in white blood cell (WBC) (22.9%) and neutrophil cell count (22.9%) (Table&#x000a0;<xref rid="cas13066-tbl-0003" ref-type="table-wrap">3</xref>). Grade 3 treatment&#x02010;related AE were observed in three patients (pulmonary thrombosis, decrease in lymphocyte cell count, and hypophosphatemia). No treatment&#x02010;related grade 4/5 AE were reported. Alectinib was interrupted or discontinued due to AE in 20% and 5.7% of patients, respectively. There were two cases of grade 1 interstitial lung disease including pneumonitis. Treatment&#x02010;related nausea was experienced by 8.6% of patients in the safety population. In the crizotinib&#x02010;failure population, all grade treatment&#x02010;related AE reported in &#x0003e;20% of patients were constipation (30.4%), dysgeusia (30.4%), and a decrease in WBC count (21.7%).</p><table-wrap id="cas13066-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>All&#x02010;grade treatment&#x02010;related adverse events in 10% or more of patients in the safety population and the crizotinib&#x02010;failure population</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Adverse event</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Safety population (<italic>n</italic>&#x000a0;=&#x000a0;35)<xref ref-type="fn" rid="cas13066-note-0005">&#x02020;</xref>
</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Crizotinib failure (<italic>n</italic>&#x000a0;=&#x000a0;23)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Number</th><th align="left" valign="top" rowspan="1" colspan="1">%</th><th align="left" valign="top" rowspan="1" colspan="1">Number</th><th align="left" valign="top" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Constipation</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">31.4</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">30.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Dysgeusia</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">25.7</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">30.4</td></tr><tr><td align="left" rowspan="1" colspan="1">WBC count decreased</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">22.9</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">21.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Neutrophil count decreased</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">22.9</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">17.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Vomiting</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">14.3</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">13.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Rash</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">14.3</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">13.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood bilirubin increased</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">14.3</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">8.7</td></tr><tr><td align="left" rowspan="1" colspan="1">AST increased</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">14.3</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">4.3</td></tr></tbody></table><table-wrap-foot><fn id="cas13066-note-0005"><p>&#x02020;Treatment&#x02010;related grade 3 adverse events were observed in 3 patients; pulmonary thrombosis (<italic>n</italic>&#x000a0;=&#x000a0;1), decrease in lymphocyte cell count (<italic>n</italic>&#x000a0;=&#x000a0;1), and hypophosphatemia (<italic>n</italic>&#x000a0;=&#x000a0;1). Data are presented as of 6 November 2014, which was the last patient's last visit. AST, aspartate aminotransferase; WBC, white blood cell.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="cas13066-sec-0012"><title>Efficacy</title><p>For patients taking the 20/40&#x02010;mg and 150&#x02010;mg capsules, median treatment duration was 13.1&#x000a0;months (range 1.1&#x02212;15.0); treatment duration by individual patient is shown in Fig.&#x000a0;S4. Of 30 patients in the FAS response&#x02010;evaluable (RE) population who had measurable lesions, 22 demonstrated tumor shrinkage of &#x0003e;30% (Fig.&#x000a0;S5). ORR in this group was 70.0% (95% CI 50.6&#x02212;85.3) and DCR was 83.3% (95% CI 65.3&#x02212;94.4), with a median time to response of 1.2&#x000a0;months (95% CI 1.1&#x02212;2.1). In the crizotinib&#x02010;failure RE population (<italic>n&#x000a0;=&#x000a0;</italic>20), ORR was 65.0% (95% CI 40.8&#x02212;84.6) and DCR was 80.0% (95% CI 56.3&#x02212;94.3) (Table&#x000a0;<xref rid="cas13066-tbl-0004" ref-type="table-wrap">4</xref>); median time to response was 1.2&#x000a0;months (95% CI 1.1&#x02212;1.3). Overall, 21&#x000a0;patients in the FAS RE population and 13 patients in the crizotinib&#x02010;failure RE population had a PR; no patient achieved a CR. The median duration of response was not estimable in either the FAS or crizotinib&#x02010;failure populations (range 2.5&#x02013;14.1&#x000a0;months).</p><table-wrap id="cas13066-tbl-0004" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>Response rates with alectinib in the overall and crizotinib&#x02010;failure populations</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Response, <italic>n</italic>
</th><th align="left" valign="top" rowspan="1" colspan="1">Total (<italic>n</italic>&#x000a0;=&#x000a0;30)<xref ref-type="fn" rid="cas13066-note-0006">&#x02020;</xref>
</th><th align="left" valign="top" rowspan="1" colspan="1">Crizotinib failure (<italic>n</italic>&#x000a0;=&#x000a0;20)<xref ref-type="fn" rid="cas13066-note-0006">&#x02021;</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Complete response</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Partial response</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">Stable disease</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Progressive disease</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">ORR, %</td><td align="left" rowspan="1" colspan="1">70.0</td><td align="left" rowspan="1" colspan="1">65.0</td></tr><tr><td align="left" rowspan="1" colspan="1">95% CI</td><td align="left" rowspan="1" colspan="1">50.6&#x02013;85.3</td><td align="left" rowspan="1" colspan="1">40.8&#x02013;84.6</td></tr><tr><td align="left" rowspan="1" colspan="1">DCR, %</td><td align="left" rowspan="1" colspan="1">83.3</td><td align="left" rowspan="1" colspan="1">80.0</td></tr><tr><td align="left" rowspan="1" colspan="1">95% CI</td><td align="left" rowspan="1" colspan="1">65.3&#x02013;94.4</td><td align="left" rowspan="1" colspan="1">56.3&#x02013;94.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Median time to response, months</td><td align="left" rowspan="1" colspan="1">1.2</td><td align="left" rowspan="1" colspan="1">1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">95% CI</td><td align="left" rowspan="1" colspan="1">1.1&#x02013;2.1</td><td align="left" rowspan="1" colspan="1">1.1&#x02013;1.3</td></tr></tbody></table><table-wrap-foot><fn id="cas13066-note-0006"><p>&#x02020;24/30 patients were crizotinib pretreated (of which, 4 patients also received ceritinib and 1 patient also received ASP3026); 1 patient received only ceritinib treatment. &#x02021;Including 3 patients who failed on ceritinib. Data are presented as of 6 November 2014, which was the last patient's last visit. CI, confidence interval; DCR, disease control rate; ORR, overall response rate.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Median PFS was 13.9&#x000a0;months (95% CI 11.1&#x02212;not reached [NR]) for all patients and 12.9&#x000a0;months (95% CI 3.9&#x02212;NR) for the crizotinib&#x02010;failure population (Fig.&#x000a0;<xref rid="cas13066-fig-0001" ref-type="fig">1</xref>). A PFS event was observed in 14&#x000a0;patients who had experienced PD with crizotinib; no events occurred in patients who had discontinued crizotinib for reasons other than PD.</p><fig fig-type="Figure" xml:lang="en" id="cas13066-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Progression&#x02010;free survival in the full analysis set and crizotinib&#x02010;failure populations.</p></caption><graphic id="nlm-graphic-3" xlink:href="CAS-107-1642-g001"/></fig></sec></sec><sec id="cas13066-sec-0013"><title>Discussion</title><p>Alectinib is approved by the Japanese Ministry of Health, Labour and Welfare for the treatment of <italic>ALK+</italic>, unresectable, advanced or recurrent NSCLC at a dose of 300&#x000a0;mg twice daily given in eight capsules (20/40&#x000a0;mg).<xref rid="cas13066-bib-0011" ref-type="ref">11</xref> In the present study, a new 150&#x02010;mg alectinib capsule showed similar bioequivalence to the 20/40&#x02010;mg capsules, and its food effect was negligible. These findings suggest that the 150&#x02010;mg capsule could be a good substitute for eight 20/40&#x02010;mg capsules, providing increased treatment administration choice for patients with <italic>ALK+</italic> NSCLC.</p><p>Alectinib was well tolerated and had an acceptable safety profile with no treatment&#x02010;related grade 4/5 AE or gastrointestinal toxicities leading to treatment withdrawal. These results are in line with the AF&#x02010;001JP study and two phase II studies of alectinib in <italic>ALK+</italic> NSCLC patients who had failed on crizotinib, despite the use of different alectinib doses.<xref rid="cas13066-bib-0011" ref-type="ref">11</xref>, <xref rid="cas13066-bib-0015" ref-type="ref">15</xref>, <xref rid="cas13066-bib-0016" ref-type="ref">16</xref>
</p><p>Although crizotinib is approved for the front&#x02010;line treatment of <italic>ALK+</italic> NSCLC, many patients who initially respond well undergo a relapse within 1&#x000a0;year of treatment.<xref rid="cas13066-bib-0017" ref-type="ref">17</xref>, <xref rid="cas13066-bib-0018" ref-type="ref">18</xref> In this study, alectinib 300&#x000a0;mg twice daily showed favorable response rates in patients with <italic>ALK+</italic> NSCLC, including those who had failed on prior crizotinib. These results are in line with preclinical studies in which alectinib led to tumor size reduction in models of crizotinib resistance.<xref rid="cas13066-bib-0019" ref-type="ref">19</xref> Even though the treatment dose was different, ORR in our study is also in agreement with data from the NP28761 study (ORR: 47.8%; DCR: 79.7%) and the NP28673 study (ORR: 50.0%; DCR 78.7%).<xref rid="cas13066-bib-0015" ref-type="ref">15</xref>, <xref rid="cas13066-bib-0016" ref-type="ref">16</xref> In addition, favorable median PFS of 13.9 and 12.9&#x000a0;months was observed in the FAS and crizotinib&#x02010;failure populations, respectively, although these estimates could be unstable because of the distribution of censored patients. Our study is, however, limited by the small sample size and larger studies are required to validate the observed results.</p><p>This study demonstrated that a new 150&#x02010;mg alectinib capsule has a similar pharmacokinetic profile to the existing 20/40&#x02010;mg capsules, providing an additional therapeutic option for patients with <italic>ALK+</italic> NSCLC. Furthermore, alectinib has promising efficacy and is well tolerated in patients with <italic>ALK+</italic> NSCLC who have progressed on prior ALK inhibitors, including those with crizotinib&#x02010;treatment history and crizotinib failures. It is of note that superior PFS with alectinib <italic>vs</italic> crizotinib has been recently demonstrated in a randomized phase&#x000a0;III study of Japanese patients with ALK inhibitor&#x02010;na&#x000ef;ve, <italic>ALK</italic>+ NSCLC (J&#x02010;ALEX; JapicCTI&#x02010;132316).<xref rid="cas13066-bib-0020" ref-type="ref">20</xref>
</p></sec><sec id="cas13066-sec-0015"><title>Disclosure Statement</title><p>TH has received honoraria from Chugai Pharmaceutical Co. Ltd. and Pfizer, research funding from Chugai Pharmaceutical Co. Ltd., Pfizer and Novartis, and has acted in a consulting/advisory role to Novartis; KN has received honoraria and research funding from Chugai Pharmaceutical Co. Ltd. and Pfizer Japan Inc, and has participated in a speakers&#x02019; bureau for these companies; T Seto has received honoraria from Chugai Pharmaceutical Co. Ltd., Pfizer Japan Inc., and Novartis Pharma K.K., and has received research funding from Chugai Pharmaceutical Co. Ltd., Pfizer Japan Inc., Novartis Pharma K.K. and Astellas Pharma Inc.; MS has received honoraria from Chugai Pharmaceutical Co. Ltd., Taiho Pharmaceutical, Eli Lilly Japan, Pfizer, AstraZeneca, Novartis and Boehringer Ingelheim, and has received research funding from Chugai Pharmaceutical Co. Ltd., AstraZeneca, Novartis, Ono Pharmaceutical, Bristol&#x02010;Myers Squibb, Eli Lilly Japan, Taiho Pharmaceutical, Pfizer Japan Inc., and MSD; MN has received honoraria from Pfizer, Chugai Pharmaceutical Co. Ltd., Eli Lilly, Taiho Pharmaceutical, Nichirei Biosciences, Elekta, AstraZeneca, Sanofi, Bristol&#x02010;Myers Squibb and Ono Pharmaceutical, has acted in a consulting/advisory role to Novartis, Ono Pharmaceutical, Chugai Pharmaceutical Co. Ltd., Eli Lilly, Taiho Pharmaceutical, Daiichi Sankyo and Pfizer, and has received research funding from Novartis, Ono Pharmaceutical, Chugai Pharmaceutical Co. Ltd., Bristol&#x02010;Myers Squibb Japan, Takeda Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Eli Lilly and Pfizer; KH has received honoraria from Chugai Pharmaceutical Co. Ltd., Eli Lilly, Taiho Pharmaceutical, Daiichi Sankyo, Pfizer, NipponKayaku, Bellinger, AstraZeneca, Sanofi and MSD, has acted in a consulting/advisory role to AstraZeneca and Eli Lilly, and has received travel/accommodation expenses from AstraZeneca; T Takahashi has participated in a speakers&#x02019; bureau for AstraZeneca K.K., Eli Lilly Japan K.K. and Ono Pharmaceutical, and has received research funding from AstraZeneca, Eli Lilly Japan K.K., Ono Pharmaceutical, MSD and Quintiles; YO has received honoraria from Chugai Pharmaceutical Co. Ltd., AstraZeneca, Eli Lilly, Pfizer, Ono Pharmaceutical, Daiichi Sankyo and Taiho Pharmaceutical, has acted in a consulting/advisory role to Chugai Pharmaceutical Co. Ltd., AstraZeneca, Eli Lilly and Boehringer Ingelheim, has received research funding from Chugai Pharmaceutical Co. Ltd., Ono Pharmaceutical, AstraZeneca, BMS, Eli Lilly, MSD and Novartis, has been paid to provide expert testimony for AstraZeneca, and has an immediate family member who is an employee of Chugai Pharmaceutical Co. Ltd.; KT has received honoraria from Chugai Pharmaceutical Co. Ltd.; MT, TA, T Shimada and T Tanaka are employees of Chugai Pharmaceutical Co. Ltd.; T Tamura has received honoraria from Chugai Pharmaceutical Co. Ltd., Taiho Pharmaceutical, Eli Lilly, Ono Pharmaceutical, Eisai, Yakult, Boehringer Ingelheim and Bristol&#x02010;Myers Squibb.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="cas13066-sup-0001"><caption><p>
<bold>Fig.&#x000a0;S1.</bold> JP28927 study design.</p></caption><media xlink:href="CAS-107-1642-s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cas13066-sup-0002"><caption><p>
<bold>Fig.&#x000a0;S2.</bold> Trial profile of patient disposition.</p></caption><media xlink:href="CAS-107-1642-s002.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cas13066-sup-0003"><caption><p>
<bold>Fig.&#x000a0;S3.</bold> Pharmacokinetic assessment of (a) the bioequivalence of 20/40&#x02010;mg capsules <italic>vs</italic> a 150&#x02010;mg capsule of alectinib and (b) the effect of food on the 150&#x02010;mg alectinib capsule.</p></caption><media xlink:href="CAS-107-1642-s003.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cas13066-sup-0004"><caption><p>
<bold>Fig.&#x000a0;S4.</bold> Treatment duration by individual patient (full analysis set).</p></caption><media xlink:href="CAS-107-1642-s004.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="cas13066-sup-0005"><caption><p>
<bold>Fig.&#x000a0;S5.</bold> Maximum percentage change in tumor size from baseline (FAS response&#x02010;evaluable population).</p></caption><media xlink:href="CAS-107-1642-s005.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="cas13066-sec-0014"><title>Acknowledgments</title><p>The authors would like to thank all participating physicians, registered patients, their families and Gardiner&#x02010;Caldwell Communications for medical writing assistance. Medical writing assistance was funded by Chugai Pharmaceutical Co. Ltd.</p></ack><ref-list content-type="cited-references" id="cas13066-bibl-0001"><title>References</title><ref id="cas13066-bib-0001"><label>1</label><mixed-citation publication-type="book" id="cas13066-cit-0001">
<string-name>
<surname>Ferlay</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Soerjomataram</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Ervik</surname>
<given-names>M</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11</article-title>. <publisher-loc>Lyon, France</publisher-loc>: <publisher-name>International Agency for Research on Cancer</publisher-name>, <year>2013</year> [Online; Cited 4 Aug 2016.] Available from URL: <ext-link ext-link-type="uri" xlink:href="http://globocan.iarc.fr">http://globocan.iarc.fr</ext-link>.</mixed-citation></ref><ref id="cas13066-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cas13066-cit-0002">
<string-name>
<surname>Chia</surname>
<given-names>PL</given-names>
</string-name>, <string-name>
<surname>Mitchell</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Dobrovic</surname>
<given-names>A</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Prevalence and natural history of ALK positive non&#x02010;small&#x02010;cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors</article-title>. <source>Clin Epidemol</source>
<year>2014</year>; <volume>6</volume>: <fpage>423</fpage>&#x02013;<lpage>32</lpage>.</mixed-citation></ref><ref id="cas13066-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cas13066-cit-0003">
<string-name>
<surname>Morris</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Kirstein</surname>
<given-names>MN</given-names>
</string-name>, <string-name>
<surname>Valentine</surname>
<given-names>MB</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non&#x02010;hodgkin's lymphoma</article-title>. <source>Science</source>
<year>1994</year>; <volume>263</volume>: <fpage>1281</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">8122112</pub-id></mixed-citation></ref><ref id="cas13066-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cas13066-cit-0004">
<string-name>
<surname>Hallberg</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Palmer</surname>
<given-names>RH</given-names>
</string-name>. <article-title>Mechanistic insight into the ALK receptor tyrosine kinase in human cancer biology</article-title>. <source>Nat Cancer Rev</source>
<year>2013</year>; <volume>13</volume>: <fpage>685</fpage>&#x02013;<lpage>700</lpage>.</mixed-citation></ref><ref id="cas13066-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cas13066-cit-0005">
<string-name>
<surname>Soda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>YL</given-names>
</string-name>, <string-name>
<surname>Enomoto</surname>
<given-names>M</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Identification of the transforming EML4&#x02010;ALK fusion gene in non&#x02010;small&#x02010;cell lung cancer</article-title>. <source>Nature</source>
<year>2007</year>; <volume>448</volume>: <fpage>561</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">17625570</pub-id></mixed-citation></ref><ref id="cas13066-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cas13066-cit-0006">
<string-name>
<surname>Shaw</surname>
<given-names>AT</given-names>
</string-name>, <string-name>
<surname>Yeap</surname>
<given-names>BY</given-names>
</string-name>, <string-name>
<surname>Mino&#x02010;Kenudson</surname>
<given-names>M</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Clinical features and outcome of patients with non&#x02010;small&#x02010;cell lung cancer who harbor EML4&#x02010;ALK</article-title>. <source>J Clin Oncol</source>
<year>2009</year>; <volume>27</volume>: <fpage>4247</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">19667264</pub-id></mixed-citation></ref><ref id="cas13066-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cas13066-cit-0007">
<string-name>
<surname>Roskoski</surname>
<given-names>R</given-names>
<suffix>Jr</suffix>
</string-name>. <article-title>Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition</article-title>. <source>Pharmacol Res</source>
<year>2013</year>; <volume>68</volume>: <fpage>68</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">23201355</pub-id></mixed-citation></ref><ref id="cas13066-bib-0008"><label>8</label><mixed-citation publication-type="miscellaneous" id="cas13066-cit-0008">
<article-title>National Comprehensive Cancer Network: Clinical Practice Guidelines for Non&#x02010;small Cell Lung Cancer</article-title>. V4.2016. [Online; Cited 4 Aug 2016.] Available from URL: <ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf">http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf</ext-link>.</mixed-citation></ref><ref id="cas13066-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cas13066-cit-0009">
<string-name>
<surname>Kwak</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Bang</surname>
<given-names>YJ</given-names>
</string-name>, <string-name>
<surname>Camidge</surname>
<given-names>DR</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Anaplastic lymphoma kinase inhibition in non&#x02010;small&#x02010;cell small&#x02010;cell lung cancer</article-title>. <source>N Engl J Med</source>
<year>2010</year>; <volume>363</volume>: <fpage>1693</fpage>&#x02013;<lpage>703</lpage>.<pub-id pub-id-type="pmid">20979469</pub-id></mixed-citation></ref><ref id="cas13066-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cas13066-cit-0010">
<string-name>
<surname>Shaw</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>DW</given-names>
</string-name>, <string-name>
<surname>Mehra</surname>
<given-names>R</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Ceritinib in ALK&#x02010;rearranged non&#x02010;small&#x02010;cell lung cancer</article-title>. <source>N Engl J Med</source>
<year>2014</year>; <volume>370</volume>: <fpage>1189</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">24670165</pub-id></mixed-citation></ref><ref id="cas13066-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cas13066-cit-0011">
<string-name>
<surname>Seto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kiura</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Nishio</surname>
<given-names>M</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>CH5424802 (RO5424802) for patients with <italic>ALK</italic>&#x02010;rearranged advanced non&#x02010;small&#x02010;cell lung cancer (AF&#x02010;001JP study): a single&#x02010;arm, open&#x02010;label, phase 1&#x02013;2 study</article-title>. <source>Lancet Oncol</source>
<year>2013</year>; <volume>14</volume>: <fpage>590</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">23639470</pub-id></mixed-citation></ref><ref id="cas13066-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cas13066-cit-0012">
<string-name>
<surname>Ohe</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nishio</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kiura</surname>
<given-names>K</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>A phase I/II study with a CNS&#x02010;penetrant, selective ALK inhibitor alectinib in <italic>ALK&#x02010;rearranged</italic> non&#x02010;small cell lung cancer (<italic>ALK+</italic> NSCLC) patients (pts): updates on progression free survival (PFS) and safety results from AF&#x02010;001JP</article-title>. <source>J Clin Oncol</source>
<year>2015</year>; <volume>33</volume> (<issue>15s</issue>): Abstract 8061.</mixed-citation></ref><ref id="cas13066-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cas13066-cit-0013">
<string-name>
<surname>Takeuchi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Togashi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kamihara</surname>
<given-names>Y</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK&#x02010;positive lung cancer (AF&#x02010;001JP study)</article-title>. <source>Ann Oncol</source>
<year>2016</year>; <volume>27</volume>: <fpage>185</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">26487585</pub-id></mixed-citation></ref><ref id="cas13066-bib-0014"><label>14</label><mixed-citation publication-type="miscellaneous" id="cas13066-cit-0014">
<collab collab-type="authors">US Food and Drug Administration</collab>
. <article-title>Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products &#x02013; general considerations</article-title>, <year>2002</year> [Online; Cited 4 Aug 2016.] Available from URL: <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM154838.pdf">http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM154838.pdf</ext-link>.</mixed-citation></ref><ref id="cas13066-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cas13066-cit-0015">
<string-name>
<surname>Gandhi</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Shaw</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gadgel</surname>
<given-names>S</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>A phase 2, open&#x02010;label, multicenter study of the ALK inhibitor alectinib in an <italic>ALK+</italic> non&#x02010;small&#x02010;cell lung cancer (NSCLC) US/Canadian population who had progressed on crizotinib (NP28761)</article-title>. <source>J Clin Oncol</source>
<year>2015</year>; <volume>33</volume> (<issue>15s</issue>): Abstract 8019.</mixed-citation></ref><ref id="cas13066-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cas13066-cit-0016">
<string-name>
<surname>Ou</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Ahn</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Petris</surname>
<given-names>L</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Efficacy and safety of the ALK inhibitor alectinib in ALK+ non&#x02010;small&#x02010;cell lung cancer (NSCLC) patients who have failed prior crizotinib: an open&#x02010;label, single&#x02010;arm, global phase 2 study (NP28673)</article-title>. <source>J Clin Oncol</source>
<year>2015</year>; <volume>33</volume> (<issue>15s</issue>): Abstract 8008.</mixed-citation></ref><ref id="cas13066-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cas13066-cit-0017">
<string-name>
<surname>Lovly</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Shaw</surname>
<given-names>AT</given-names>
</string-name>. <article-title>Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies</article-title>. <source>Clin Cancer Res</source>
<year>2014</year>; <volume>20</volume>: <fpage>2249</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">24789032</pub-id></mixed-citation></ref><ref id="cas13066-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cas13066-cit-0018">
<string-name>
<surname>Ou</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>J&#x000e4;nne</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Bartlett</surname>
<given-names>CH</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced <italic>ALK</italic>&#x02010;positive NSCLC</article-title>. <source>Ann Oncol</source>
<year>2014</year>; <volume>25</volume>: <fpage>415</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">24478318</pub-id></mixed-citation></ref><ref id="cas13066-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cas13066-cit-0019">
<string-name>
<surname>Kodama</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tsukaguchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yoshida</surname>
<given-names>M</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance</article-title>. <source>Cancer Lett</source>
<year>2014</year>; <volume>351</volume>: <fpage>215</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">24887559</pub-id></mixed-citation></ref><ref id="cas13066-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cas13066-cit-0020">
<string-name>
<surname>Nokihara</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hida</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kondo</surname>
<given-names>M</given-names>
</string-name>
<italic>et&#x000a0;al</italic>
<article-title>Alectinib (ALC) versus crizotinib (CRZ) in ALK&#x02010;inhibitor naive ALK&#x02010;positive non&#x02010;small cell lung cancer (ALK+ NSCLC): primary results from the J&#x02010;ALEX study</article-title>. <source>J Clin Oncol</source>
<year>2016</year>; <volume>34</volume> (<issue>15s</issue>): Abstract 9008.</mixed-citation></ref></ref-list></back></article>